The goal of the consortium: a clinical study

With the previous grant from the Dutch Heart Foundation, they researched certain molecules in the heart and in particular the role of RNA – a "photocopy" of our DNA. "If you don’t want a mistake responsible for heart failure in the DNA to be copied, you have to stick a kind of patch onto the damaged DNA," says De Windt. The aim of the consortium is to start a clinical trial with a drug that uses RNA technology in four years.

How RNA technology can help with hereditary heart failure

When the body reads DNA to make new proteins, the double-stranded structure of DNA is separated. One strand serves as a template for a transcribed single strand: RNA. Such an RNA strand can be replicated in the lab. "If it is then inserted into one of the coronary arteries via a catheter, we can force the body to only translate information from the intact chromosome, thus making the heart function properly. This RNA technology has already been proven effective in other studies," says De Windt. Patients would have to take this medicine repeatedly, but not three times a day, like current heart failure drugs.

Link between fundamental and clinical research

The consortium focuses on those forms of heart failure current medication has the least effect on. Twenty percent of all heart failure patients in the Netherlands suffer from an inherited form of heart disease; an estimated 40,000 patients. The most aggressive form is called 'dilated cardiomyopathy' (DCM). Prof. Yigal Pinto is a cardiologist at the Amsterdam UMC and one of the doctors treating most of these patients. He is also Professor of Molecular Biology of Heart Failure in Amsterdam. "I share with Leon de Windt a great interest in new biological approaches to the heart muscle. And in addition to that scientific click, there is certainly a personal click, which speeds up progress." Together they represent the entire research chain; from fundamental scientific research to clinical treatment of patients.